Streetbeat News

Regulatory

JNJ

Johnson & Johnson has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending full approval for Sirturo, a treatment for multidrug-resistant tuberculosis. This marks a significant step forward in the fight against this challenging health issue.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:17 pm

EIS

ISRA

SPY

USO

The U.S. has issued a warning that any action by the International Criminal Court (ICC) against Israel could potentially harm the chances of achieving a cease-fire. This statement underscores the delicate balance of international diplomacy and the potential impact of legal actions on peace processes.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:13 pm

MRNA

MYNZ

PFE

mRNA technology, known for its role in COVID-19 vaccines by Pfizer and Moderna, is now promising breakthroughs in cancer diagnostics and treatment. Mainz Biomed reported significant findings from a clinical study on its ColoAlert® CRC screening test, showing high sensitivity and specificity rates. The study, involving 690 subjects across the U.S. and Europe, used novel mRNA biomarkers and a proprietary AI algorithm. Moderna, in partnership with OpenAI, is advancing mRNA medicine further by integrating AI technologies like a customized version of ChatGPT, mChat, into its operations.

Portfolio Pulse from Upwallstreet

April 29, 2024 | 2:02 pm

TSLA

Tesla Inc's Model 3 and Model Y have passed China's data security requirements, a crucial step for deploying its full self-driving (FSD) software in China. The China Association of Automobile Manufacturers confirmed the compliance of these models along with others from companies like BYD, Ideal, Lotus, Hezhong New Energy, and NIO. This development follows CEO Elon Musk's recent visit to China and a partnership with Baidu Inc for navigation data, indicating progress towards launching FSD in the Chinese market.

Portfolio Pulse from Anan Ashraf

April 29, 2024 | 2:02 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced positive Phase 2 trial data for Tacrolimus Inhalation Powder (TFF TAC) for lung transplant rejection prevention, presented at the ISHLT Annual Meeting. The data show TFF TAC prevents rejection with lower doses and systemic exposures than oral tacrolimus, and normalizes rejection-related gene expressions. The company plans to advance the program into potentially registrational testing.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:01 pm

AAPL

AMZN

GOOGL

META

MSFT

The European Commission has labeled Apple Inc.'s iPadOS as a 'gatekeeper' under the Digital Markets Act, affecting Apple and other tech giants like Alphabet Inc., Microsoft Corporation, Amazon.com Inc., and Meta Platforms Inc. This designation requires compliance with the DMA, potentially impacting Apple's operations and financials due to the risk of significant fines for non-compliance. The announcement follows a week of mixed news for Apple, including product updates and challenges in the market.

Portfolio Pulse from Benzinga Neuro

April 29, 2024 | 1:45 pm

IMMX

Immix Biopharma has been awarded the European Union Orphan Drug Designation for NXC-201, aimed at treating multiple myeloma. This designation grants NXC-201 ten years of market exclusivity in the EU, access to the EU centralized authorization procedure, and reduced fees for various regulatory and marketing processes.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:39 pm

AZN

DSKYF

DSNKY

AstraZeneca reported positive results from a metastatic breast cancer treatment study for Enhertu, showing significant improvement in progression-free survival. Additionally, AstraZeneca's Truqap, in combination with Faslodex, is recommended for approval in the EU for certain breast cancer patients. Daiichi Sankyo, co-developer of Enhertu, also plays a role in these developments.

Portfolio Pulse from Vandana Singh

April 29, 2024 | 1:26 pm

BYDDF

NIO

TSLA

China's industrial association has released a list of 76 intelligent connected vehicle models that comply with the country's auto data security standards, including models from Tesla, BYD, Li Auto, Lotus, Hozon New Energy Automobile, and NIO. The vehicles underwent tests for compliance with data anonymization, non-collection of in-car data, in-car data processing, and notification of personal information processing, starting in November 2023.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:19 pm

MULN

Mullen Automotive's stock is trading higher following the announcement that the California Air Resources Board has approved the 2024 Mullen THREE for inclusion in the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:17 pm